AstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer Treatment
05 Mayo 2022 - 2:03AM
Noticias Dow Jones
By Michael Susin
AstraZeneca PLC said on Thursday that its metastatic breast
cancer treatment Enhertu has been approved for use in the U.S.
The Anglo-Swedish pharma giant said Enhertu will be used in
patients with breast cancer that were treated with a prior
treatment and have developed disease recurrence during or within
six months of completing therapy.
The company said clinical studies showed that the treatment has
reduced the risk of disease progression or death by 72% when
compared with other treatment.
Enhertu its a jointly treatment developed and commercialized by
AstraZenecaa and Daiichi Sankyo Co.
Astrazeneca said regulatory applications are currently under
review in Europe, Japan and several other countries.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
May 05, 2022 02:48 ET (06:48 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Daiichi Sankyo Company Ltd (PK) (OTCMarkets): 0 recent articles
Más de Daiichi Sankyo Company Ltd (PK) Artículos de Noticias